Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET
- Coppola A.
- Castaman G.
- Santoro R. C.
- Mancuso M. E.
- Franchini M.
- Marino R.
- Rivolta G. F.
- Santoro C.
- Zanon E.
- Sciacovelli L.
- Manca S.
- Lubrano R.
- Golato M.
- Tripodi A.
- Rocino A.
- Bernardini S.
- Biasoli C.
- Borchiellini A.
- Cultrera D.
- De Cristofaro R.
- Di Minno G.
- Gamba G.
- Giampaolo A.
- Giuffrida A. C.
- Giuffrida C.
- Gresele P.
- Mazzucconi M. G.
- Morfini M.
- Hassan H. J.
- Molinari A. C.
- Pollio B.
- Sargentini V.
- Tagliaferri A.
- Tosetto A.
- Zampogna S.
DOIAbstract
Introduction: The factor VIII (FVIII)-mimetic bispecific monoclonal antibody, emicizumab, previously approved for prophylaxis in haemophilia A with inhibitors, has been recently licensed in several countries also in patients with severe haemophilia A (PWSHA) without inhibitors. The introduction of this innovative agent requires the development of specific pathways at Haemophilia Treatment Centres (HTC), particularly regarding laboratory testing and treatment of breakthrough bleeds and invasive procedures/surgeries, even more critical when patients are managed by non-specialist professionals. Limited literature data and clinical experience in PWSHA without inhibitors on emicizumab are currently available. Aim: To promote awareness and overco...
Add to ORKG